3,4-diaminopyridine


Also found in: Wikipedia.

3,4-diaminopyridine

a parasympathomimetic agent, similar to 4-aminopyridine.
Mentioned in ?
References in periodicals archive ?
Zesiewicz of the University of South Florida in Tampa, found that they could not recommend leve-tiracetam and 3,4-diaminopyridine as second-line agents, based on quality (level B) clinical evidence that they do not reduce limb tremor.
This trial used Fampridine's chemical cousin, 3,4-diaminopyridine.
along with the rights to a proprietary form of 3,4-diaminopyridine, amifampridine phosphate, an experimental treatment for Lambert Eaton Myasthenic Syndrome (LEMS).
Studies have also been conducted with the potassium channel blockers 4-aminopyridine and 3,4-diaminopyridine (neither is currently marketed in the United States).
The aminopyridines (4-aminopyridine [AP] and 3,4-diaminopyridine [DAP]) are potassium channel blockers shown to improve nerve conduction in experimentally demyelinated axons.
Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and 3,4-diaminopyridine (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).
Nasdaq: BMRN) announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

Full browser ?